This session demonstrates the feasibility of transcatheter aortic valve implantation (TAVI) in patients with heart failure through a series of challenging cases. It covers sequential management of hypertrophic obstructive cardiomyopathy with aortic stenosis, advanced heart failure interventions, staged approaches in cardiogenic shock, and complex percutaneous interventions...

This session explores recent advancements in drug-eluting stent (DES) technology, featuring global real-world evidence on short dual antiplatelet therapy (DAPT) with polymer-free DES, angiographic outcomes from pooled TARGET trials, and real-world registry data on various DES platforms. It also presents post-marketing surveillance results and systematic reviews...

An 85‑year‑old man with type 2 diabetes mellitus, hypertension, dyslipidemia, peripheral artery disease, COPD, and chronic kidney disease presented with CCS class II angina related to three‑vessel coronary artery disease. He had previously undergone hybrid revascularization, including PCI of the RCA ostium and CABG with LIMA...

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

There is no doubt that the original Stent for Life initiative had a huge, positive impact on morbidity and mortality in patients with STEMI in Europe. With the global Stent – Save a Life! (SSL) initiative comes the continued spread of the mission to other regions,...

Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

In this article, Ulrich Schäfer explores the evolving landscape of access strategies in transcatheter aortic valve implantation (TAVI). While the transfemoral approach remains the gold standard, a significant proportion of patients are not suitable due to peripheral vascular disease or anatomical constraints.
Drawing on clinical evidence and...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)